Clinical Trials - Cancer Institute

The Scott & White Cancer Institute currently offers clinical trials for the following disease sites. Protocols are updated monthly to reflect currently open trials.

---

Cancer Prevention and Control Studies

• MDACC 2005-0328 - A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients with Metastatic Breast and Colorectal Cancer (NCI Protocol CCC-03-26)
• MDACC 2004-0728 - Prevention of Cisplatin-Or Oxaliplatin-Induced Peripheral Neuropathy with Alpha-Lipoic: A Placebo-Controlled Phase III Trial
• MDACC 2004-0024 - Chemotherapy and Mindfulness Relaxation: A Randomized Trial at M.D. Anderson Cancer Center and M.D. Anderson Community Clinical Oncology Program
• HLMCC 0502 - Thyroid Function & Breast Cancer: A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed with Breast Cancer and the Magnitude of Change in Thyroid Function Post Chemotherapy
• HLMCC 0501 - Stress Management Therapy for Patients Undergoing Chemotherapy for Cancer

Back to Top

---

Brain

There are no studies at this time.

Back to Top

---

Breast

Adjuvant Node Positive, Node Negative, Unknown

• SWOG S0221 - Phase III Trial of Continuous Schedule AC+G versus Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
• NSABP B-36 - A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC), With or Without Celecoxib, in Patients with Node-Negative Breast Cancer
• CTSU NCIC-CTG MA.27 - Randomized Phase III Trial of Exemestane Versus Anastrazole With or Without Celecoxib in Post-Menopausal Women with Receptor Positive Primary Breast Cancer
• ECOG PACCT-1 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
• CTSU IBCSG 24-02 - A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (Suppression of Ovarian Function Trial- SOFT)
• NSABP FB5 - Phase III Clinical Trial of Epirubicin plus Cyclophosphamide followed by Docetaxel plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer
• ECOG E5103 - A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (NCI CIRB)

Metastatic

• MDACC 2005-0328 - A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients with Metastatic Breast and Colorectal Cancer (NCI Protocol CCC-03-26)
• 050319 - A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin^TM ) in Patients with Refractory Advanced Solid Tumor Malignancies
• SWOG S0500 - A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at the First Follow-Up Assessment
• 060778 - An Observed Study of Avastin (Bevacizumab) in combination with Chemotherapy for Treatment of Metastatic or Locally Advanced Disease in Breast, Non Small Cell Lung, and Colorectal Cancer
• ECOG E1105 - A Randomized Phase III Double-Blind Placebo- Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over Expressing Metastatic Breast Cancer (NCI CIRB)

Inflammatory, Locally Advanced

• NSABP FB5 - Phase III Clinical Trial of Epirubicin plus Cyclophosphamide followed by Docetaxel plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer

Other

• ECOG E2Z04 - Quality of Life in Younger Breast Cancer Survivors
• HLMCC 0502 - Thyroid Function & Breast Cancer: A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed with Breast Cancer and the Magnitude of Change in Thyroid Function Post Chemotherapy

Back to Top

---

Gastrointestinal

Rectal

• NSABP R-04 - A Clinical Trial of Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum
• ECOG E5204 - Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorourcil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation

Colorectal

• CTSU NCCTG N0147 - A Randomized Phase III Trial of Oxaliplatin Plus 5-FU/Leucovorin with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer
• 8725 - Non-Invasive Detection of Human Epithelial Cell Gene Expression Profiles Using Exfoliated Colonocytes: Development of Robust Classifiers for Colon Cancer and Pre-Cancerous Inflammatory Bowel Disease

Metastatic

• MDACC 2005-0328 - A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients with Metastatic Breast and Colorectal Cancer (NCI Protocol CCC-03-26)
• 050325 - A Multicenter, Randomized Double-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-Line Treatment of Patients with Metastatic Colorectal Cancer Treated with Oxaliplatin/5-FU/LV
• 050319 - A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin^TM ) in Patients with Refractory Advanced Solid Tumor Malignancies
• SWOG S0600 - A Phase III Trial of Irinotecan-Based Chemotherapy Plus Centuximab with or without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX , OPTIMOX or XELOX
• 060778 - An Observational Study of Avastin (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced Disease in Breast, Non Small Cell Lung, and Colorectal Cancer
• 071346 - Blinded, Randomized, Phase 1/2 Study of Brivanib Alinate vs Placebo in Combination with Erbitux and Irinotecan in Subjects with Metastatic Colorectal Cancer
• 060778 - An Observational Study of Avastin (BEVACIZUMAB) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced Disease in Breast, NSCL, and Colorectal

Gastric or Gastroesophageal

• CALGB 80101 - Phase III Intergroup of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma

Esophageal

• SWOG S0356 - Oxaliplatin plus Protracted Infusion 5-FU and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial with Molecular Correlates
• ECOG E1206 - A Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer

Pancreatic

• 071186 - Phase 2, Multicenter, Open Label Study of CS-1008, A humanized Monocional Antibody Targeting Death Receptor 5 (DR5), In Combination with Gemcitabine in Chemotherapy Naive Subjects with Unresectable or Metastatic Pancreatic Cancer
• 071228 - A Phase 2b Randomized, Double-Blinded, Multicenter Trial of Amplimexon plus Gemcitabine versus Gemcitabine plus Amplimexon Placebo in Patients with Metastatic Chemotherapy Naive Pancreatic Adenocarcinoma

Other

• MDACC 2004-0728 - Prevention of Cisplatin-Or Oxaliplatin-Induced Peripheral Neuropathy with Alpha-Lipoic: A Placebo-Controlled Phase III Trial

Back to Top

---

Genitourinary

Prostate

• 060674 - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer Renal

Renal

• ECOG E2805 - A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
• ECOG E4805 - A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVEOO5 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma

Bladder Cancer

• SWOG S0353 - Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG

Back to Top

---

Gynecologic

• 050319 - A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin^TM) in Patients with Refractory Advanced Solid Tumor Malignancies

Endometrial

• GOG 0209 - A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel/G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III and IV or Recurrent Endometrial Cancer

Ovarian

• GOG 212 - A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Month Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
• GOG 218 - A Phase III Trial of Carboplatin/Paclitaxel + Placebo Versus Carboplatin/Paclitaxel + Concurrent Bevacizumab Followed by Placebo Versus Carboplatin/Paclitaxel + Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Peritoneal Primary Cancer

Vulvar

• GOG 173 - Intraoperative Lymphatic Mapping in Patients with Stage I and II Squamous Cell Carcinoma of the Vulva

Back to Top

---

Head and Neck

There are no studies at this time

Back to Top

---

Leukemia/Lymphoma/Myeloma

Acute Myeloid Leukemia

• 22304 - Fusion Protein Therapy of Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) with DT388IL3: A Phase I/II Clinical Trial

Leukemia

• SWOG S0530 - A Phase II Trial of Cytarabine and Clofarabine in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
• ECOG E2903 - Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia
• E1905 - A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia
• ECOG E1905 - A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrone, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia

Non-Hodgkin's Lymphoma

• 070947 - A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Back to Top

---

Lung

• 050319 - A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin^TM) in Patients with Refractory Advanced Solid Tumor Malignancies

Non-Small Cell

• SWOG E5597 - Phase III Chemoprevention trial of Selenium supplementation in persons with resected Stage I Non-Small Cell Lung Cancer
• ECOG E1505 - A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with completely Resected IB (>/= 4cm) - IIIA Non-Small Cell Lung Cancer
• 070969 - Phase 1/2 Study of Pemetrexed (Alimta®) plus Carboplatin, or Pemetrexed plus Cisplatin with Concurrent Radiation Therapy Followed by Every-21 Day Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B NSCLC
• 060778 - An Observational Study of Avastin (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced Disease in Breast, Non Small Cell Lung, and Colorectal Cancer

Bronchioalveolar Carcinoma

• ECOG E1504 - Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features

Other

• MDACC 2004-0728 - Prevention of Cisplatin-Or Oxaliplatin-Induced Peripheral Neuropathy with Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trial

Back to Top

---

Melanoma

Melanoma

• E1697 - Phase III Randomized Adjuvant Study of High-Dose Interferon alfa-2b Therapy in Patients with Stage II or III Melanoma

Back to Top

---

Miscellaneous

Other

• MDACC 2005-0328 - A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients with Metastatic Breast and Colorectal Cancer (NCI Protocol CCC-03-26)
• MDACC 2004-0024 - Chemotherapy and Mindfulness Relaxation: A Randomized Trial at M.D. Anderson Cancer Center and M.D. Anderson Community Clinical Oncology Program
• HLMCC 0501 - Stress management therapy for patients undergoing chemotherapy
• 060862 - A Multi-Center, Open Label Trial to Evaluate the Evaluate the Efficacy and Tolerability of Aprepitant and Palonesetron for the Prevention of Chemotherapy Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
• MDACC 2004-0728 - Prevention of Cisplatin-Or Oxaliplatin-Induced Peripheral Neuropathy with Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trial

Solid Tumor

• 050319 - A Phase I Pharmacokinetics and Safety Study of Chimeric Anti-Phosphatidylserine Monoclonal Antiboey (Tarvacin) in Subjects with Advanced Solid Tumor Malignancies
• 060672 - An Open-Label, Multicenter Extension Study of Chimeric Ant-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients with Refractory Advanced Solid Tumor Malignancies (Must have completed 050319)

---

Clinical Trial Information:

For additional clinical trial information and screening for eligibility, please contact the Scott & White Center for Cancer Prevention and Care at 800-882-4366 or 254-724-1053.

Back to Top